Drugs / TSC-203-A0201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05973487 | May 2024 → Dec 2026 expected | adenosquamous carcinoma, anal squamous cell carcinoma, anogenital human papillomavirus infection, endocervical adenocarcinoma +8 | TScan Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-09 | TScan Therapeutics, Inc. | Regulatory TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update tscan.com ↗
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program. |
| 2023-08-29 | TScan Therapeutics, Inc. | Regulatory TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME tscan.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in Melanoma (PRAME). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-09 | TScan Therapeutics, Inc. | TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update tscan.com ↗ |
| 2023-08-29 | TScan Therapeutics, Inc. | TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME tscan.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSC-203-A0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05973487 ↗ |
| Target | PRAME | “TSC-203-A0201 targeting PRAME on HLA-A\*02:01” NCT05973487 ↗ |